Lantheus is a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow® disease.
For over 65 years, Lantheus has provided the nuclear medicine market first-in-class diagnostic radiopharmaceutical products including TechneLite® (Technetium Tc 99m Generator), NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), and Xenon Xe-133 Gas. The launch of the most successful diagnostic radiopharmaceutical in history, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), solidified our commitment to healthcare and innovation.
This site is intended for U.S. Healthcare Professionals only.
PM-US-CA-0018 November 2022